{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-019393","form_type":"8-K","ticker":"AIM","cik":"0000946644","company_name":"AIM ImmunoTech Inc.","filed_at":"2023-05-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.963840+00:00","generated_at":"2026-06-14T12:25:51.391983+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"AIM ImmunoTech enters research agreement with Japan's NIID to study Ampligen's effect on viral shedding","bullets":["Agreement with Japanese National Institute of Infectious Disease to evaluate Ampligen's capacity to prevent viral shedding in respiratory virus infections.","AIM supplies Ampligen free of charge; NIID conducts research; quarterly oral updates and final written report within 60 days.","Intellectual property ownership follows US inventorship law; no automatic license granted to NIID.","Agreement terminates upon completion, written agreement, or one year from effective date (May 8, 2023)."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-019393","json":"https://secwatch.observer/filing/0001493152-23-019393.json","markdown":"https://secwatch.observer/filing/0001493152-23-019393.md","text":"https://secwatch.observer/filing/0001493152-23-019393.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/946644/000149315223019393/0001493152-23-019393-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/946644/000149315223019393/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T12:25:51.391983+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d5d6f5ece6888963ddf168dc293a158e6fa09085","claim":"AIM ImmunoTech Inc. entered into Material Transfer and Research Agreement with Japanese National Institute of Infectious Disease (effective 2023-05-22).","evidence_excerpt":"On May 22, 2023, AIM ImmunoTech Inc. (the “Company”) and the Japanese National Institute of Infectious Disease (the “JNIID”) entered into a Material Transfer and Research Agreement (the “Agreement).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/946644/000149315223019393/0001493152-23-019393-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Japanese National Institute of Infectious Disease"},{"label":"Effective","value":"2023-05-22"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}